Patents by Inventor Marion OTT

Marion OTT has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMBINATION THERAPY OF ANTIBODIES ACTIVATING HUMAN CD40 AND ANTIBODIES AGAINST HUMAN PD-L1
    Publication number: 20200095313
    Abstract: The present invention relates to a pharmaceutical product for the treatment of a proliferative disease, comprising the combination of an antibody, or an antigen-binding portion thereof, that specifically binds to human CD40; and a PD-L1 antibody; and optionally a 3rd component which comprises as an active ingredient a cytokine inhibitor.
    Type: Application
    Filed: December 11, 2019
    Publication date: March 26, 2020
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Emily Rana CORSE, Olivier FREYTAG, Christian GERDES, Marine LE CLECH, Hyam LEVITSKY, Marion OTT, Martin STERN, Wei XU
  • COMBINATION THERAPY OF ANTIBODIES ACTIVATING HUMAN CD40 AND ANTIBODIES AGAINST HUMAN PD-L1
    Publication number: 20180051077
    Abstract: The present invention relates to a pharmaceutical product for the treatment of a proliferative disease, comprising the combination of an antibody, or an antigen-binding portion thereof, that specifically binds to human CD40; and a PD-L1 antibody; and optionally a 3rd component which comprises as an active ingredient a cytokine inhibitor.
    Type: Application
    Filed: October 2, 2017
    Publication date: February 22, 2018
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Emily Rana Corse, Olivier Freytag, Christian Gerdes, Marine Le Clech, Hyam Levitsky, Marion OTT, Martin Stern, Wei Xu
  • COMBINATION THERAPY OF ANTIBODIES ACTIVATING HUMAN CD40 AND ANTIBODIES AGAINST HUMAN PD-L1
    Publication number: 20160045597
    Abstract: The present invention relates to a pharmaceutical product for the treatment of a proliferative disease, comprising the combination of an antibody, or an antigen-binding portion thereof, that specifically binds to human CD40; and a PD-L1 antibody; and optionally a 3rd component which comprises as an active ingredient a cytokine inhibitor.
    Type: Application
    Filed: August 14, 2015
    Publication date: February 18, 2016
    Applicant: HOFFMANN-LA ROCHE INC.
    Inventors: Emily Rana CORSE, Olivier FREYTAG, Christian GERDES, Marine LE CLECH, Hyam LEVITSKY, Marion OTT, Martin STERN, Wei XU